Hunan Nucien Pharmaceutical Co., Ltd. (SHA:688189)
China · Delayed Price · Currency is CNY 6.25
-0.28 (-4.29%)
At close: Jul 30, 2026
SHA:688189 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 127.34 | 141.92 | 251.7 | 720.05 | 698.8 | 743.11 |
Other Revenue | 0.01 | 0.01 | 0.02 | 0.01 | 0.02 | 0.55 |
| 127.35 | 141.93 | 251.72 | 720.06 | 698.83 | 743.66 | |
Revenue Growth | -18.35% | -43.62% | -65.04% | 3.04% | -6.03% | -27.74% |
Cost of Revenue | 104.69 | 104.71 | 129.61 | 121.53 | 117.85 | 106.77 |
Gross Profit | 22.66 | 37.21 | 122.12 | 598.53 | 580.98 | 636.89 |
Selling, General & Admin | 83.32 | 86.11 | 156.21 | 422.37 | 486.81 | 656.18 |
Research & Development | 29.19 | 35.36 | 48.81 | 74.86 | 58.16 | 78.03 |
Other Operating Expenses | 1.17 | 1.56 | 4.87 | 9.86 | 9.43 | 10.43 |
Operating Expenses | 132.28 | 138.23 | 470.1 | 594.2 | 660.57 | 853.05 |
Operating Income | -109.62 | -101.02 | -347.98 | 4.33 | -79.6 | -216.16 |
Interest Expense | -2.38 | -3.58 | -5.4 | -15.25 | -22.03 | -15.92 |
Interest & Investment Income | 3.05 | 3.55 | 6.97 | 10.77 | 16.76 | 21.45 |
Currency Exchange Gain (Loss) | - | - | -0.02 | - | -0.07 | 0.03 |
Other Non Operating Income (Expenses) | -0.42 | -0.08 | -0.07 | -0.51 | -0.3 | -3.54 |
EBT Excluding Unusual Items | -109.38 | -101.13 | -346.5 | -0.66 | -85.23 | -214.15 |
Impairment of Goodwill | - | - | -10.85 | - | -2.72 | -14.69 |
Gain (Loss) on Sale of Investments | - | - | - | -14.91 | -5.63 | - |
Gain (Loss) on Sale of Assets | 2.52 | 2.52 | 0.59 | 0.17 | - | - |
Asset Writedown | -33.41 | -34.62 | -21.14 | - | -0.02 | -2.03 |
Other Unusual Items | 0.48 | 0.48 | 1.2 | 6.25 | 19.6 | 16.08 |
Pretax Income | -139.79 | -132.75 | -376.68 | -9.14 | -74.01 | -214.79 |
Income Tax Expense | 16.67 | 17.01 | 8.64 | 1.65 | 23.61 | -32.3 |
Earnings From Continuing Operations | -156.45 | -149.75 | -385.32 | -10.79 | -97.61 | -182.48 |
Minority Interest in Earnings | 14.34 | 12.85 | 38.82 | -0.08 | 18.78 | 20.6 |
Net Income | -142.12 | -136.9 | -346.51 | -10.87 | -78.83 | -161.88 |
Net Income to Common | -142.12 | -136.9 | -346.51 | -10.87 | -78.83 | -161.88 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 274 | 274 | 274 | 274 | 274 | 274 |
Shares Outstanding (Diluted) | 274 | 274 | 274 | 274 | 274 | 274 |
Shares Change | 0.06% | 0.00% | -0.02% | 0.03% | -0.01% | 6.66% |
EPS (Basic) | -0.52 | -0.50 | -1.26 | -0.04 | -0.29 | -0.59 |
EPS (Diluted) | -0.52 | -0.50 | -1.26 | -0.04 | -0.29 | -0.59 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -45.86 | 34.77 | -57.03 | 183.74 | -201.1 | -176.7 |
Free Cash Flow Per Share | -0.17 | 0.13 | -0.21 | 0.67 | -0.73 | -0.64 |
Gross Margin | 17.79% | 26.22% | 48.51% | 83.12% | 83.14% | 85.64% |
Operating Margin | -86.08% | -71.18% | -138.24% | 0.60% | -11.39% | -29.07% |
Profit Margin | -111.59% | -96.46% | -137.65% | -1.51% | -11.28% | -21.77% |
Free Cash Flow Margin | -36.01% | 24.50% | -22.66% | 25.52% | -28.78% | -23.76% |
EBITDA | -75.55 | -66.27 | -310.52 | 40.23 | -32.94 | -178.55 |
EBITDA Margin | -59.32% | -46.69% | -123.36% | 5.59% | -4.71% | -24.01% |
D&A For EBITDA | 34.08 | 34.75 | 37.46 | 35.89 | 46.66 | 37.61 |
EBIT | -109.62 | -101.02 | -347.98 | 4.33 | -79.6 | -216.16 |
EBIT Margin | -86.08% | -71.18% | -138.24% | 0.60% | -11.39% | -29.07% |
Revenue as Reported | 127.35 | 141.93 | 251.72 | 720.06 | 698.83 | 743.66 |
Advertising Expenses | - | 37.65 | 92.62 | 331.97 | - | 0.16 |